Publication
Effectiveness and safety of levosimendan in clinical practice
| dc.contributor.author | Silva-Cardoso, J | |
| dc.contributor.author | Ferreira, J | |
| dc.contributor.author | Oliveira-Soares, A | |
| dc.contributor.author | Martins-de-Campos, J | |
| dc.contributor.author | Fonseca, C | |
| dc.contributor.author | Lousada, N | |
| dc.contributor.author | Ilídio-Moreira, J | |
| dc.contributor.author | Rabaçal, C | |
| dc.contributor.author | Damasceno, A | |
| dc.contributor.author | Amorim, S | |
| dc.contributor.author | Seabra-Gomes, R | |
| dc.contributor.author | Ferreira, R | |
| dc.contributor.author | Abreu-Lima, C | |
| dc.date.accessioned | 2012-08-17T13:17:04Z | |
| dc.date.available | 2012-08-17T13:17:04Z | |
| dc.date.issued | 2009 | |
| dc.description.abstract | BACKGROUND: In previous randomized studies levosimendan improved hemodynamics and clinical course, with a still unclear effect on prognosis. There are, however, few data regarding its effects when used in daily practice. AIMS: We evaluated the clinical effectiveness and safety of levosimendan in the treatment of acute systolic heart failure (SHF) in daily practice conditions. METHODS: In this prospective, multicenter, nonrandomized trial, a continuous infusion of levosimendan (0.05 microg/kg/min-0.2 microg/kg/min) was administered for 24 hours. An optional loading dose of 12 microg/kg over 10 minutes was used. The primary combined endpoint of clinical effectiveness (as defined by a eight-variable clinical score) and safety (defined by the absence of serious adverse events) was assessed at 24 hours after the beginning of treatment; a second similar primary combined endpoint was assessed at 5 days. RESULTS: One hundred and twenty-nine consecutive patients requiring inotropes despite optimal oral background heart failure therapy were recruited. The primary endpoint was reached in 80.6% at 24 hours and in 79.7% at 5 days. During the six months before levosimendan the number of patient days of hospitalization for heart failure was 14.9 +/- 14.6 versus 3.1 +/- 7.6 during the six months following levosimendan (p < 0.001). CONCLUSIONS: In daily practice, levosimendan was clinically effective and safe in 80.6% and 79.7% of patients with acute SHF at 24 hours and 5 days respectively after the beginning of treatment. A marked reduction in the number of days of hospitalization for heart failure was also seen during the subsequent six months. | por |
| dc.identifier.citation | Rev Port Cardiol. 2009 Feb;28(2):143-54 | por |
| dc.identifier.issn | 0870-2551 | |
| dc.identifier.uri | http://hdl.handle.net/10400.10/656 | |
| dc.language.iso | eng | por |
| dc.peerreviewed | yes | por |
| dc.publisher | Sociedade Portuguesa de Cardiologia | por |
| dc.subject | Insuficiência cardíaca | por |
| dc.subject | Levosimendam | por |
| dc.subject | Heart failure | por |
| dc.subject | Levosimendan | por |
| dc.title | Effectiveness and safety of levosimendan in clinical practice | por |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.conferencePlace | Lisboa | por |
| oaire.citation.endPage | 154 | por |
| oaire.citation.startPage | 143 | por |
| oaire.citation.title | Revista Portuguesa de Cardiologia | por |
| oaire.citation.volume | 28 | por |
| rcaap.rights | openAccess | por |
| rcaap.type | article | por |